News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
24,221 Results
Type
Article (1087)
Company Profile (5)
Press Release (23129)
Multimedia
Podcasts (3)
Webinars (2)
Section
Business (8566)
Career Advice (15)
Deals (1300)
Drug Development (3089)
Employer Resources (2)
FDA (440)
Job Trends (655)
News (13196)
Policy (840)
Tag
Academia (54)
Adcomms (1)
Allergies (10)
Alliances (1463)
ALS (25)
Alzheimer's disease (46)
Antibody-drug conjugate (ADC) (23)
Approvals (463)
Artificial intelligence (10)
Autoimmune disease (6)
Automation (1)
Bankruptcy (9)
Best Places to Work (619)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (3)
Bladder cancer (14)
Brain cancer (1)
Breast cancer (15)
Cancer (223)
Cardiovascular disease (15)
Career advice (11)
Career pathing (1)
CAR-T (12)
Cell therapy (37)
Cervical cancer (2)
Clinical research (2907)
Collaboration (63)
Compensation (77)
Complete response letters (1)
COVID-19 (66)
C-suite (57)
Cystic fibrosis (4)
Data (367)
Depression (8)
Diabetes (12)
Diagnostics (181)
Digital health (2)
Diversity, equity & inclusion (1)
Drug discovery (5)
Drug pricing (1)
Drug shortages (1)
Duchenne muscular dystrophy (4)
Earnings (3297)
Editorial (2)
Employer resources (2)
Events (3843)
Executive appointments (90)
FDA (608)
Frontotemporal dementia (1)
Funding (74)
Gene editing (5)
Generative AI (1)
Gene therapy (22)
GLP-1 (14)
Government (79)
Guidances (28)
Healthcare (608)
HIV (6)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (4)
Immuno-oncology (2)
Indications (4)
Infectious disease (82)
Inflammatory bowel disease (7)
Influenza (5)
Intellectual property (13)
Interviews (2)
IPO (580)
Job creations (150)
Job search strategy (9)
Layoffs (14)
Legal (215)
Liver cancer (4)
Lung cancer (25)
Lymphoma (26)
Machine learning (3)
Management (1)
Manufacturing (24)
MASH (15)
Medical device (325)
Medtech (325)
Mergers & acquisitions (790)
Metabolic disorders (50)
Multiple sclerosis (25)
NASH (3)
Neurodegenerative disease (8)
Neuropsychiatric disorders (3)
Neuroscience (148)
NextGen: Class of 2025 (276)
Non-profit (114)
Now hiring (1)
Obesity (21)
Opinion (2)
Ovarian cancer (19)
Pain (9)
Pancreatic cancer (4)
Parkinson's disease (26)
Patents (19)
Patient recruitment (19)
Peanut (7)
People (3875)
Pharmaceutical (4)
Phase I (913)
Phase II (1434)
Phase III (900)
Pipeline (226)
Policy (7)
Postmarket research (27)
Preclinical (317)
Prostate cancer (14)
Psychedelics (3)
Radiopharmaceuticals (16)
Rare diseases (33)
Real estate (218)
Regulatory (732)
Reports (1)
Research institute (83)
Resumes & cover letters (3)
RSV (10)
Schizophrenia (13)
Series A (15)
Series B (10)
Service/supplier (1)
Sickle cell disease (4)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (285)
The Weekly (3)
Vaccines (46)
Weight loss (3)
Women's health (6)
Worklife (1)
Date
Today (3)
Last 7 days (46)
Last 30 days (171)
Last 365 days (2197)
2025 (1778)
2024 (2952)
2023 (1952)
2022 (1488)
2021 (1847)
2020 (1867)
2019 (1376)
2018 (1072)
2017 (922)
2016 (905)
2015 (1136)
2014 (909)
2013 (827)
2012 (814)
2011 (778)
2010 (742)
Location
Africa (14)
Alabama (1)
Arizona (6)
Asia (1330)
Australia (246)
California (683)
Canada (215)
China (29)
Colorado (43)
Connecticut (24)
Delaware (12)
Europe (2946)
Florida (59)
Georgia (21)
Idaho (2)
Illinois (96)
India (13)
Indiana (34)
Japan (29)
Kansas (1)
Kentucky (1)
Maryland (56)
Massachusetts (739)
Michigan (58)
Minnesota (8)
Missouri (1)
Montana (1)
Nevada (3)
New Hampshire (1)
New Jersey (338)
New York (168)
North Carolina (66)
Northern California (281)
Ohio (14)
Oklahoma (1)
Pennsylvania (280)
Puerto Rico (1)
South America (17)
Southern California (315)
Tennessee (7)
Texas (55)
United States (2855)
Utah (45)
Virginia (6)
Washington D.C. (1)
Washington State (96)
Wisconsin (14)
24,221 Results for "curia formerly amri".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year
October 22, 2025
·
2 min read
Business
Curia Appoints Niall Condon to Lead Manufacturing
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced the appointment of Niall Condon as president of its Manufacturing Division, with immediate effect.
August 2, 2022
·
2 min read
Deals
Integrity Bio and LakePharma Become Curia
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand.
February 14, 2022
·
2 min read
Business
Curia Appoints Gerald Auer as Chief Financial Officer
Curia, a leading contract research, development and manufacturing organization, announced that Gerald Auer has been appointed as chief financial officer.
December 15, 2023
·
1 min read
Biotech Bay
Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities
Berkeley Lights, Inc., a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.
June 6, 2022
·
4 min read
Metabolic disorders
Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath
The death occurred in a patient who had a complex medical background and who was being managed with several drugs, according to RBC Capital.
October 21, 2025
·
2 min read
·
Tristan Manalac
Pharm Country
Curia wins 2023 Frost & Sullivan Customer Value Leadership Award
Curia, a leading contract research, development and manufacturing organization, announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan.
June 29, 2023
·
2 min read
Business
Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, and Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer and to treat autoimmune and inflammatory disorders and other diseases using self-replicating RNA (srRNA), today announced that they will collaborate on a robust development platform for Replicate’s srRNA therapeutics.
June 9, 2022
·
3 min read
Deals
Curia Completes Acquisition of LakePharma
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has completed the transaction to acquire LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts and Texas
September 2, 2021
·
2 min read
Drug Development
Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA VaccineSupply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)
Curia today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has dosed the first participant with RBI-4000, a self-replicating (srRNA) rabies vaccine, in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.
September 13, 2023
·
2 min read
1 of 2,423
Next
